Abilify (aripiprazole) is the first atypical antipsychotic approved for ADD-ON therapy for depression

Abilify (aripiprazole) is the first atypical antipsychotic approved for ADD-ON therapy for depression.

Seroquel XR (quetiapine) is already approved for MONOTHERAPY for depression when other antidepressants fail.

Up to two-thirds of patients with depression still have symptoms despite an adequate trial of an antidepressant.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote